Opening Day: Scribe Therapeutics makes strong trading debut
Scribe Therapeutics makes its public debut above issue price as the CRISPR drug developer opened for trading last week. The biotech entered the market with cardiometabolic programs at the forefront and early momentum behind its platform story. LATEST IPOS AND DIRECT LISTINGS: Scribe Therapeutics (SCTX) opened on July 24 at $25. Scribe, which priced 8.58M shares at $15.00, describes itself as a clinical-stage biotechnology company engineering CRISPR-based technologies into "purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases," starting with cardiometabolic disease. RECENT SPAC IPOS: Market Technology Acquisition (MTAK) opened on July 24 at $10.00. The company's primary focus is businesses operating "across the global capital markets ecosystem, with particular emphasis on licensed U.S. equities and options clearing businesses and related market infrastructure, and post-trade, brokerage, custody, execution and financial technology platforms." B&R Technology Merger (BRTM) opened on July 21 at $9.96. The company may pursue an initial business combination target in any business or industry..
Scribe Therapeutics makes its public debut above issue price as the CRISPR drug developer opened for trading last week.
The biotech entered the market with cardiometabolic programs at the forefront and early momentum behind its platform story.
LATEST IPOS AND DIRECT LISTINGS: Scribe Therapeutics (SCTX) opened on July 24 at $25.
Scribe, which priced 8.58M shares at $15.00, describes itself as a clinical-stage biotechnology company engineering CRISPR-based technologies into "purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases," starting with cardiometabolic disease.
RECENT SPAC IPOS: Market Technology Acquisition (MTAK) opened on July 24 at $10.00.
The company's primary focus is businesses operating "across the global capital markets ecosystem, with particular emphasis on licensed U.S. equities and options clearing businesses and related market infrastructure, and post-trade, brokerage, custody, execution and financial technology platforms." B&R Technology Merger (BRTM) opened on July 21 at $9.96.
The company may pursue an initial business combination target in any business or industry..